Serum FABP4 levels were positively associated with suspected liver steatosis assessed by the fatty liver index (FLI) in both normal glucose tolerance subjects [23] and patients at increased cardiometabolic risk, including diabetic, obese, and metabolic syndrome patients [30]. The gene discussed is FABP4; the disease is Hepatic steatosis.